ホーム › 胃癌 › ミシガン州 › Grand Rapids
Grand Rapids、MIにおける胃癌の臨床試験
Grand Rapidsとその周辺地域（約30マイル以内）の拠点で、胃癌に関する18件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
被験者募集中健康なボランティア歓迎
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
- Trinity Health Grand Rapids Hospital, Grand Rapids
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
被験者募集中第2相
- Research Site, Grand Rapids
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
被験者募集中第1相
- BAMF Health Inc., Grand Rapids
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
被験者募集中第1相
- BAMF Health Inc., Grand Rapids
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- START Midwest, Grand Rapids
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
被験者募集中第1/2相
- START Midwest, Grand Rapids
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
被験者募集中第3相
- Research Site, Grand Rapids
A Phase 1/1b Study of IAM1363 in HER2 Cancers
被験者募集中第1相
- START - Midwest Cancer Research Center, Grand Rapids
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
被験者募集中第1/2相
- START Midwest, LLC, Grand Rapids
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Research Site, Grand Rapids
A Study of MGC026 in Participants With Advanced Solid Tumors
被験者募集中第1相
- START Midwest, Grand Rapids
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
被験者募集中第1相
- START Midwest, Grand Rapids
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
被験者募集中第1相
- START Midwest /ID# 248685, Grand Rapids
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
被験者募集中第2/3相
- BAMF Health, Grand Rapids
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
被験者募集中第2相
- Research Site, Grand Rapids
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
被験者募集中第1/2相
- START Midwest, Grand Rapids
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
被験者募集中第1/2相
- BAMF Health, Inc., Grand Rapids
他の都市における胃癌の試験
- Houston, TX42件の研究
- Boston, MA32件の研究
- New York City, NY31件の研究
- Nashville, TN28件の研究
- Baldwin Park, CA22件の研究
- Los Angeles, CA22件の研究
- Arlington, VA20件の研究
- Dallas, TX19件の研究
- San Antonio, TX19件の研究
- St. Louis, MO18件の研究
- Washington, DC16件の研究
- Chicago, IL16件の研究
Grand Rapidsにおける他の研究
- 非小細胞肺癌44件の研究
- 大腸癌40件の研究
- がん（全種類）28件の研究
- 乳がん26件の研究
- 卵巣がん24件の研究
- 転移性癌22件の研究
- 前立腺がん19件の研究
- 子宮内膜がん18件の研究
- 膵臓がん18件の研究
- 悪性黒色腫17件の研究
- 頭頸部扁平上皮癌15件の研究
- トリプルネガティブ乳がん15件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。